Long‐term effects of androgen deprivation therapy in prostate cancer patients
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Summary: background Prostate cancer (PCa) is one of the most common cancers in men and has an increasing incidence. In 1999, 37 000 men died from PCa in the USA. Androgen deprivation therapy (ADT) with GnRH agonists is frequently employed in the treatment of recurrent and metastatic PCa by inducing medical castration, rendering these men hypogonadal. Because hypogonadism in men is associated with a wide range of complications, we attempted to determine the effects of long‐term ADT in men with PCa. methods We conducted a cross‐sectional study at a tertiary care centre to determine the effect of ADT on lean body mass (LBM), muscle strength, bone mineral density (BMD), sexual function, and quality of life (QOL) in men with PCa. Three groups of men were enrolled: (1) 20 men with PCa who were undergoing medical castration with GnRH agonists for at least 12 months prior to the onset of the study (ADT group); (2) 18 age‐matched men with nonmetastatic PCa who were post prostatectomy and/or radiotherapy but had not yet undergone ADT (non‐ADT group); and (3) 20 age‐matched normal men who were healthy and ambulatory (control group). results Men on ADT had castrate levels of serum total testosterone (P < 0·0001), free testosterone (P < 0·0001) and oestradiol (P < 0·0001), which were significantly lower than in the other groups. Total body (P = 0·03) and lumbar spine (P < 0·0001) BMD was significantly lower in patients on ADT compared to other groups and was associated with higher levels of urinary N‐telopeptide (P = 0·02). The ADT group had higher fat mass compared to the other groups (P = 0·0001) and significantly reduced upper body strength (P = 0·001) when compared to non‐ADT patients. The ADT group had lower overall scores on Watt's Sexual Function Questionnaire compared to other groups (P = 0·0001), in particular a decrease in desire, arousal and frequency of spontaneous early morning erections. The ADT group also had lower overall QOL scores, resulting in significant limitation of physical function (P = 0·001), role limitation (P = 0·02) and perception of physical health (P = 0·004). conclusions This study suggests that osteoporosis, unfavourable body composition, sexual dysfunction and reduced quality of life are seen in patients receiving androgen deprivation therapy for at least 12 months. Longitudinal studies in this patient population will shed further light on the timing of the development and the extent of these complications. Meanwhile, this information will assist both physicians and patients with prostate cancer to make informed decisions regarding androgen deprivation therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Landis, S. H., Murray, T., Bolden, S., & Wingo, P. A. (1999) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.8 · Cited by 3,068
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471 · cited 1×
“Men with oestrogen receptor mutations and aromatase deficiency have severe osteoporosis despite having normal androgen levels (Smith et al., 1994; Bilezikian et al., 1998).”
BackgroundKatznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791 · cited 2×
“These include decline in lean body mass (LBM), muscle strength and bone density (Katznelson et al., 1996), and osteoporosis (Seeman, 1997).”
BackgroundPamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer
Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A., Kantoff, P. W., & Finkelstein, J. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010845 · Cited by 696
Increased Bone Mass as a Result of Estrogen Therapy in a Man with Aromatase Deficiency
Bilezikian, J. P., Morishima, A., Bell, J., & Grumbach, M. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390905 · Cited by 625
Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis
Urban, R. J., Bodenburg, Y. H., Gilkison, C., Foxworth, J., Coggan, A. R., Wolfe, R. R., & Ferrando, A. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.269.5.e820 · Cited by 608 · cited 1×
“Testosterone administration in these men results in an increase in muscle mass and strength (Urban et al., 1995; Wolfe et al., 2000).”
BackgroundPROGRESSIVE OSTEOPOROSIS DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER
DANIELL, H. W., DUNN, S. R., FERGUSON, D. W., LOMAS, G., NIAZI, Z., & STRATTE, P. T. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)68000-7 · Cited by 452
ŠTĚPÁN, J. J., LACHMAN, M., ZVĚŘINA, J., PACOVSKÝ, V., & BAYLINK, D. J. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-3-523 · Cited by 424
RE: OSTEOPOROSIS AFTER ORCHIECTOMY FOR PROSTATE CANCER
Krongrad, A., Levis, S., & Roos, B. A. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64271-x · Cited by 339
Osteoporosis After Orchiectomy for Prostate Cancer
Daniell, H. W. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65165-6 · Cited by 315
MAILLEFERT, J. F., SIBILIA, J., MICHEL, F., SAUSSINE, C., JAVIER, R. M., & TAVERNIER, C. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61639-2 · Cited by 308
Jw, F., Samuels, A. I., & La, M. (1971) · PubMed · Cited by 285
Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report
Larry Goldenberg, S., Bruchovsky, N., Gleave, M. E., Sullivan, L. D., & Akakura, K. (1995) · Urology · doi:10.1016/s0090-4295(99)80092-2 · Cited by 284
Shahidi, N. T. (1973) · New England Journal of Medicine · doi:10.1056/nejm197307122890205 · Cited by 263
Townsend, M. F., Sanders, W. H., Northway, R. O., & Graham, S. D. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3<545::aid-cncr17>3.0.co;2-3 · Cited by 260
BURRIS, A. S., BANKS, S. M., CARTER, C. S., DAVIDSON, J. M., & SHERINS, R. J. (1992) · Journal of Andrology · doi:10.1002/j.1939-4640.1992.tb00319.x · Cited by 259 · cited 13×
“We conducted a cross-sectional study to determine the effect of ADT on LBM, muscle strength, BMD, sexual function and QOL in men with PCa.”
BackgroundInfluentialDiamond, T., Campbell, J., Bryant, C., & Lynch, W. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981015)83:8<1561::aid-cncr11>3.0.co;2-z · Cited by 246
Bone Loss in Men with Prostate Cancer Treated with Gonadotropin-Releasing Hormone Agonists1
Stoch, S. A., Parker, R. A., Chen, L., Bubley, G., Ko, Y.-J., Vincelette, A., & Greenspan, S. L. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7558 · Cited by 186
Goldray, D. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.2.288 · Cited by 174
Androgen deprivation therapy for prostate cancer results in significant loss of bone density
Wei, J. T., Gross, M., Jaffe, C. A., Gravlin, K., Lahaie, M., Faerber, G. J., & Cooney, K. A. (1999) · Urology · doi:10.1016/s0090-4295(99)00301-5 · Cited by 169
Avioli, L. V. (1983) · Cited by 163
Bone Loss in Men with Prostate Cancer Treated with Gonadotropin-Releasing Hormone Agonists
Stoch, S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.6.2787 · Cited by 150
Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study
Higano, C. S., Ellis, W., Russell, K., & Lange, P. H. (1996) · Urology · doi:10.1016/s0090-4295(96)00381-0 · Cited by 141
Pathogenesis of Vertebral Crush Fractures in Men
BAILLIE, S. P., DAVISON, C. E., JOHNSON, F. J., & FRANCIS, R. M. (1992) · Age and Ageing · doi:10.1093/ageing/21.2.139 · Cited by 139
Risks Versus Benefits of Testosterone Therapy in Elderly Men
Basaria, S. S., & Dobs, A. S. (1999) · Drugs & Aging · doi:10.2165/00002512-199915020-00006 · Cited by 95
Self-citationSeeman, E. (1997) · Baillière s Clinical Rheumatology · doi:10.1016/s0950-3579(97)80023-4 · Cited by 78
Sexual Function with Advancing Age
Morley, J. E., & Kaiser, F. E. (1989) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30611-3 · Cited by 64
Testosterone and Muscle Protein Metabolism
Wolfe, R. R., Ferrando, A. A., Sheffield‐Moore, M., & Urban, R. J. (2000) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(19)30644-5 · Cited by 50
Cited by
Wu, F. C. W., Tajar, A., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F., Forti, G., Giwercman, A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1972 · Cited by 939
“Men with acquired hypogonadism develop redistributed and increased fat mass ( 35 ), whereas T replacement in hypogonadalmenreducedfatmass(36).However,effectsofTtreatment onfatmassaremodestinmagnitude,amountingtonomorethan 2–3 kg decrease or less than 6% loss of fat mass on whole-body dual-energy x-ray absorptiometry,…”
BackgroundAdverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Nguyen, P. L., Alibhai, S. M. H., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., & Smith, M. R. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.010 · Cited by 831
Self-citation(2005) · doi:10.1016/j.ucl.2005.08.007 · Cited by 759
Vanderschueren, D., Vandenput, L., Boonen, S., Lindberg, M. K., Bouillon, R., & Ohlsson, C. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0003 · Cited by 717
Galvão, D. A., Taaffe, D. R., Spry, N., Joseph, D., & Newton, R. U. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2488 · Cited by 657
“AST can negatively affect muscle strength and function.(3,36) Our program resulted in a significant improvement in upper and lower body muscle strength compared with usual care.”
Background
Metadata
- Authors
- Basaria, S., Lieb, J., Tang, A. M., DeWeese, T., Carducci, M., Eisenberger, M., & Dobs, A. S.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2002-06
- Volume
- 56
- Issue
- 6
- Pages
- 779-786
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2076445987
- Cited by
- 359
- References
- 30
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.